Literature DB >> 12171528

Bisphosphonates as a foundation of drug delivery to bone.

Hasan Uludag1.   

Abstract

Bisphosphonates are organic analogues of pyrophosphate that are resistant to hydrolysis. Bisphosphonates exhibit an exceptional affinity to bone, which led to exploration of their utility for targeting pharmacological agents to bone. Among the pharmacological agents explored for bone delivery are radioisotopes, anti-neoplastic drugs, agents intended for augmentation of systemic bone mass, anti-inflammatory drugs and proteins. This review is intended to provide a summary of the literature on bisphosphonate-based drug delivery. A survey of therapeutic agents designed for bone targeting was provided in the first part of this review. Special emphasis was placed on the preclinical performance of the developed agents. In the second part, several aspects that were considered critical for the success of bisphosphonate-based drug delivery were explored. These aspects were oral bioavailability, protein binding of BPs, the nature of a BP-drug linkage and the choice of bone-affinity molecule. This article concludes with the author's perspective on the future of bisphosphonate-based drug delivery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171528     DOI: 10.2174/1381612023393585

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  22 in total

1.  Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone.

Authors:  Jivan N Yewle; David A Puleo; Leonidas G Bachas
Journal:  Bioconjug Chem       Date:  2011-12-05       Impact factor: 4.774

2.  A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Authors:  Monica M Reinholz; Shawn P Zinnen; Amylou C Dueck; David Dingli; Gregory G Reinholz; Leslie A Jonart; Kathleen A Kitzmann; Amy K Bruzek; Vivian Negron; Abdalla K Abdalla; Bonnie K Arendt; Anthony J Croatt; Luis Sanchez-Perez; David P Sebesta; Harri Lönnberg; Toshiyuki Yoneda; Karl A Nath; Diane F Jelinek; Stephen J Russell; James N Ingle; Thomas C Spelsberg; Henry B F Hal Dixon; Alexander Karpeisky; Wilma L Lingle
Journal:  Bone       Date:  2010-03-15       Impact factor: 4.398

3.  188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.

Authors:  Amal A El-Mabhouh; John R Mercer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

4.  Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.

Authors:  Joseph K Agyin; Bindu Santhamma; Sudipa S Roy
Journal:  Bioorg Med Chem Lett       Date:  2013-09-21       Impact factor: 2.823

5.  Absorption-Enhancing Mechanisms of Capryol 90, a Novel Absorption Enhancer, for Improving the Intestinal Absorption of Poorly Absorbed Drugs: Contributions to Trans- or Para-Cellular Pathways.

Authors:  Hiroki Ukai; Ayako Imanishi; Ayaka Kaneda; Erika Kimura; Miku Koyama; Masaki Morishita; Hidemasa Katsumi; Akira Yamamoto
Journal:  Pharm Res       Date:  2020-11-23       Impact factor: 4.200

6.  Imparting bone affinity to glycoproteins through the conjugation of bisphosphonates.

Authors:  Sébastien A Gittens; John R Matyas; Ronald F Zernicke; Hasan Uludağ
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

7.  Modular 'click-in-emulsion' bone-targeted nanogels.

Authors:  Daniel A Heller; Yair Levi; Jeisa M Pelet; Joshua C Doloff; Jasmine Wallas; George W Pratt; Shan Jiang; Gaurav Sahay; Avi Schroeder; Josh E Schroeder; Yieu Chyan; Christopher Zurenko; William Querbes; Miguel Manzano; Daniel S Kohane; Robert Langer; Daniel G Anderson
Journal:  Adv Mater       Date:  2012-12-27       Impact factor: 30.849

8.  Impact of tether length on bone mineral affinity of protein-bisphosphonate conjugates.

Authors:  Sébastien A Gittens; Pavel I Kitov; John R Matyas; Raimar Löbenberg; Hasan Uludağ
Journal:  Pharm Res       Date:  2004-04       Impact factor: 4.200

9.  Ligand-modified aminobisphosphonate for linking proteins to hydroxyapatite and bone surface.

Authors:  Robin S Ehrick; Marcello Capaccio; David A Puleo; Leonidas G Bachas
Journal:  Bioconjug Chem       Date:  2007-11-15       Impact factor: 4.774

10.  Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.

Authors:  Robyn K Fuchs; Roger J Phipps; David B Burr
Journal:  J Bone Miner Res       Date:  2008-10       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.